GOODWILL AND OTHER INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS

6. GOODWILL AND OTHER INTANGIBLE ASSETS

Goodwill was attributable to the acquisition of our Pharma Solutions business in July 2019. The original carrying value of the intangible assets acquired was $15.6 million, with goodwill of approximately $8.3 million and identifiable intangible assets of approximately $7.3 million recorded upon acquisition. With the sale of Pharma Solutions, the goodwill balance at September 30, 2022 was written down to zero as well as the intangible assets associated with the original acquisition. The net carrying value of the identifiable intangible assets from all acquisitions within continuing operations as of September 30, 2022 and December 31, 2021 are as follows:

			As of September 30, 2022			As of December 31, 2021
	Life		Carrying			Carrying
	(Years)		Amount			Amount
				(unaudited)
Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141
Barrett’s test		9		6,682			6,682
CLIA Lab		2.3		609			609
Total			$	31,951		$	31,951
Accumulated Amortization				(30,772	)		(29,819	)
Net Carrying Value			$	1,179		$	2,132

Amortization expense from continuing operations was approximately $0.3 million and $0.9 million for the three-month periods ended September 30, 2022 and 2021, and $1.0 million and $2.7 million for the nine-month periods ended September 30, 2022 and 2021, respectively. Estimated future amortization expense for the remainder of 2022 and thereafter is as follows:

2022		2023		2024		2025		2026		Total
$	318	$	861	$	-	$	-	$	-	$	1,179

The following table displays a roll forward of the carrying amount of goodwill from December 31, 2021 to September 30, 2022:

	Carrying
	Amount
Balance as of December 31, 2021	$	8,433
Impairment from sale of Pharma Solutions Business		(8,433	)
Balance as of September 30, 2022	$	-